BridgeBio Pharma, Inc.
$76.03-$2.15 (-2.8%)
Last close · Data as of Nov 20, 2026
- Market cap
- $13.2B
- P/E
- -18.2x
- EV / EBITDA
- -26.4x
- Revenue
- $502.1M
- Net margin
- -144.4%
- ROCE
- -77.5%
Price chart
Technical chartScreen technicals →+17.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- +12.6%
- 3M
- -8.3%
- 6M
- +11.4%
- 1Y
- +17.7%
- 5Y
- Hidden
- This period includes a one-day price step on 27 Dec 2021 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$2.15 (-2.8%) from $78 to $76 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BBIO, bought on each weekday since 2021.
News & filings
What BridgeBio Pharma filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernShareholders' equity is negative: liabilities exceed assets.
Strengths (1)
- Revenue more than doubled in fiscal 2025.
- The stored ratios (as of 11 Jun 2026) describe a profitable period while fiscal 2025 shows a net loss: the two cover different periods, so the ratio points are not shown.
- Shareholders' equity is negative, so return on equity and debt to equity are not shown.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
Read moreShow less
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
- Sector
- Healthcare
- Shares outstanding
- 194.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $13.2B
- P/E
- -18.2x
- P/B
- -6.3x
- EV / EBITDA
- -26.4x
- EV / Sales
- 28.8x
- P/S
- 26.3x
- 52-week high
- $90.17
- 52-week low
- $63.30
Profitability
- Operating margin
- -100.0%
- Net margin
- -144.4%
- EBITDA margin
- -109.3%
- ROE
- 34.7%
- ROCE
- -77.5%
- ROA
- -77.4%
- Asset turnover
- 0.54
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $502.1M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 126.3%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 86.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 35.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$455.5M
Solvency
- Current ratio
- 2.77
- Debt / Equity
- -0.89
- Debt / Assets
- 1.99
- CFO / Net profit
- 0.62
- Cash / Market cap
- 4.3%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $502.1M |
| Cost of revenue | $21.0M |
| Gross profit | $481.1M |
| Operating expenses | $983.2M |
| Research and development | $451.9M |
| Selling, general and administrative | $531.2M |
| Operating income | -$502.1M |
| Interest and other | -$230.4M |
| Pretax income | -$732.5M |
| Tax and other | -$7.6M |
| Net income | -$724.9M |
Revenue and net profit
Revenue grew 126.3% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $77.6M | -$481.2M |
| FY2023 | $9.3M | -$643.2M |
| FY2024 | $221.9M | -$535.8M |
| FY2025 | $502.1M | -$724.9M |
Cash flows
FY2025: -$445.9M from operations, -$455.5M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$419.5M | -$425.8M |
| FY2023 | -$527.7M | -$529.0M |
| FY2024 | -$520.7M | -$529.6M |
| FY2025 | -$445.9M | -$455.5M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $502.1M+126.3%1Y
- EBITDA
- -$548.8M
- Net profit
- -$724.9M
- Cash from operations
- -$445.9M
- Free cash flow
- -$455.5M
- Revenue CAGR, 3Y
- 86.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $502.1M | -$548.8M | -$724.9M | -$455.5M | 34.7% | +126.3% | +35.3% |
Monthly returns
Month-by-month returns of BBIO across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $936.0M |
| Current assets | $797.8M |
| Non-current assets | $138.3M |
| Liabilities | $3.0B |
| Current liabilities | $288.0M |
| Non-current liabilities | $2.7B |
| Equity | -$2.1B |
| Paid-in capital | $2.1B |
| Retained earnings | -$3.8B |
| Treasury stock | $323.3M |
| Minority interest | $10.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BBIO highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Nuvalent, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc.BBIOthis company | $13.2B | -18.2x | -6.3x | 34.7% | -26.4x |
| Guardant Health, Inc.GH | $17.6B | -42.4x | -177.7x | 419.2% | -50.7x |
| Axsome Therapeutics, Inc.AXSM | $11.9B | -65.0x | 134.9x | -207.5% | -70.2x |
| Madrigal Pharmaceuticals, Inc.MDGL | $11.4B | -39.4x | 18.9x | -47.8% | -43.5x |
| Arrowhead Pharmaceuticals, Inc.ARWR | $10.6B | -6491.0x | 22.7x | -0.3% | 65.9x |
| Cytokinetics, IncorporatedCYTK | $9.8B | — | — | 119.0% | — |
| The Ensign Group, Inc.ENSG | $9.6B | 27.9x | 4.3x | 15.4% | 19.9x |
| ImmunityBio, Inc.IBRX | $7.6B | -21.7x | -15.3x | 70.2% | -36.1x |
| Nuvalent, Inc.NUVL | $7.4B | -17.5x | 5.9x | -34.1% | — |
| Peer median | — | -39.4x | 5.9x | 7.5% | -39.8x |
Year-to-date ROI
BBIO since 1 January, against earlier years.
Historical volatility
BBIO's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -603.3% |
| FY2023 | -6445.6% |
| FY2024 | -260.2% |
| FY2025 | -100.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $502.1M |
| Cost of revenueCost Of Revenue | $21.0M |
| Gross profitGross Profit | $481.1M |
| Operating expensesOperating Expense | $983.2M |
| Research and developmentResearch And Development | $451.9M |
| Selling, general and administrativeSelling General And Administration | $531.2M |
| Total expensesTotal Expenses | $1.0B |
| Operating incomeOperating Income | -$502.1M |
| Interest and other | |
| Pretax incomePretax Income | -$732.5M |
| TaxTax Provision | $440.0k |
| Net incomeNet Income | -$724.9M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $936.0M |
| Current assetsCurrent Assets | $797.8M |
| Non-current assetsTotal Non Current Assets | $138.3M |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.0B |
| Current liabilitiesCurrent Liabilities | $288.0M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $2.7B |
| EquityTotal Equity Gross Minority Interest | -$2.1B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$445.9M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$445.9M |
| Net income, continuing operationsNet Income From Continuing Operations | -$732.9M |
| Depreciation and amortisationDepreciation And Amortization | $5.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $5.4M |
| Stock-based compensationStock Based Compensation | $133.0M |
| Operating gains and lossesOperating Gains Losses | $84.9M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$8.8M |
| Gain loss on sale of businessGain Loss On Sale Of Business | $0.00 |
| Unrealized gain loss on investment securitiesUnrealized Gain Loss On Investment Securities | -$21.3M |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $72.6M |
| Asset impairmentAsset Impairment Charge | — |
| Change in working capitalChange In Working Capital | -$51.1M |
| Other non-cash itemsOther Non Cash Items | $136.0M |
| Investing cash flowInvesting Cash Flow | -$24.5M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$24.5M |
| Capital expenditureCapital Expenditure | -$9.6M |
| Purchase of PP&EPurchase Of PPE | -$1.1M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$1.1M |
| AcquisitionsPurchase Of Business | $0.00 |
| Net acquisitions and disposalsNet Business Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$28.2M |
| Sale of investmentsSale Of Investment | $11.0M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$17.2M |
| Purchase of intangiblesPurchase Of Intangibles | -$8.5M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | -$8.5M |
| Dividends received (investing)Dividends Received Cfi | $2.3M |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | $359.3M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $359.3M |
| Debt issuedIssuance Of Debt | $575.0M |
| Debt repaidRepayment Of Debt | -$459.0M |
| Net debt issuedNet Issuance Payments Of Debt | $116.0M |
| Long-term debt issuedLong Term Debt Issuance | $575.0M |
| Long-term debt repaidLong Term Debt Payments | -$459.0M |
| Net long-term debt issuedNet Long Term Debt Issuance | $116.0M |
| Shares issuedIssuance Of Capital Stock | $0.00 |
| Common stock issuedCommon Stock Issuance | $0.00 |
| Net common stock issuedNet Common Stock Issuance | -$62.5M |
| Common stock repurchasedCommon Stock Payments | -$62.5M |
| Share buybacksRepurchase Of Capital Stock | -$62.5M |
| Stock options exercisedProceeds From Stock Option Exercised | $34.1M |
| Other financing chargesNet Other Financing Charges | $271.6M |
| Change in cashChanges In Cash | -$111.1M |
| Cash at the start of the yearBeginning Cash Position | $683.2M |
| Cash at the end of the yearEnd Cash Position | $572.1M |
| Free cash flowFree Cash Flow | -$455.5M |
| Supplemental |
Learn while you research
Academy chapters picked for BridgeBio Pharma, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing126% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read